
ENDRA Life Sciences Inc.
97
Recent developments highlight ENDRA's clinical progress, regulatory activities, merger advancement, and stock trading events.
- ENDRA reported a Q2 2026 financial result where losses swung to profit and advanced its merger with Noble Africa, reflecting operational progress and strategic activity [N1].
- The TAEUS device achieved MRI-level liver imaging precision, underscoring technological advancement in non-invasive liver diagnostics [N2].
- Clinical studies demonstrated strong consistency for the TAEUS liver device, supporting its clinical reliability [N3].
- Ascendiant Capital maintained a buy recommendation on ENDRA Life Sciences, indicating positive analyst sentiment [N4].
- Trading of ENDRA shares was halted and resumed multiple times in late 2024 due to volatility and compliance issues, which have since been resolved [N7][N8].
- ENDRA announced a strategic public offering deal in mid-2024, indicating capital raising efforts to support operations [N7].
ENDRA Life Sciences Inc. operates in the medical device sector, specializing in ultrasound-based imaging technology for liver diagnostics. Its flagship product, the TAEUS system, has received CE mark approval for European markets and is undergoing FDA regulatory review through a de novo classification pathway. The company focuses on non-invasive imaging solutions that aim to provide MRI-level precision for liver disease detection and monitoring. ENDRA's business model involves clinical validation, regulatory approvals, and commercialization of its TAEUS applications. The company is currently engaged in a merger process with Noble Africa, which introduces additional strategic considerations. Financially, ENDRA reported a net loss in Q3 2026 but maintains strong liquidity with a current ratio near 8 and a cash ratio above 2. The company faces typical medical device industry risks including intellectual property protection, regulatory compliance, and clinical trial enrollment challenges.
Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. ENDRA Life Sciences Inc. develops ultrasound-based medical imaging devices focused on liver applications. The company has achieved CE mark approval for its TAEUS FLIP system and is pursuing FDA clearance via a de novo process for its MASLD TAEUS device. Recent clinical studies demonstrate strong consistency and MRI-level precision for its liver imaging technology. ENDRA reported a net loss of $1.53 million and EPS of -1.02 for Q3 2026, with strong liquidity ratios as of September 30, 2026. The company is advancing a merger with Noble Africa, subject to multiple conditions. Risks include intellectual property challenges, regulatory compliance, and potential delays or failure in merger completion.
The company has demonstrated technological advancement with its TAEUS device achieving MRI-level liver imaging precision and strong clinical study results, supporting potential adoption in diagnostic imaging. CE mark approval enables access to European markets, and ongoing FDA de novo submission efforts could expand U.S. market opportunities. The merger with Noble Africa may provide strategic benefits including capital infusion and expanded operational capabilities. Strong liquidity ratios provide financial flexibility to support clinical and regulatory activities. Positive analyst recommendations and recent stock price appreciation reflect market interest in the company's progress [N1][N4].
Risks include the possibility that the FDA may not grant the desired Class II clearance for the MASLD TAEUS device, potentially requiring more costly and time-consuming PMA approval. Intellectual property challenges such as patent disputes or inability to protect trade secrets could erode competitive positioning. The merger with Noble Africa is subject to multiple conditions and may not complete, potentially disrupting business focus and incurring significant costs. Regulatory compliance burdens and potential delays in clinical trial enrollment could impede product commercialization. The company reported a net loss and negative EPS, indicating ongoing operational losses and reliance on capital.
ENDRA's moat is primarily based on its proprietary ultrasound imaging technology, TAEUS, which has demonstrated MRI-level precision and strong clinical consistency. The company holds intellectual property rights including patents and trade secrets, although it faces risks related to patent enforcement and potential infringement litigation. Regulatory approvals such as CE mark and ongoing FDA clearance efforts provide market access barriers for competitors. The specialized nature of the technology and clinical validation requirements contribute to competitive differentiation. However, the medical device industry is characterized by rapid innovation and extensive patent litigation, which may challenge sustained competitive advantage.
• Regulatory Approval Risks: The MASLD TAEUS device is under FDA review via a de novo process; failure to obtain Class II clearance could require more rigorous PMA approval, delaying or limiting commercialization [S1].
• Intellectual Property Risks: ENDRA faces risks related to patent maintenance costs, potential infringement litigation, and challenges in protecting trade secrets, which could impact competitive positioning and market share [S1].
• Merger Completion Risks: The merger with Noble Africa is subject to multiple conditions including stockholder approval and regulatory clearances; failure to complete the merger could adversely affect business operations and stock price [S2].
• Clinical Trial Enrollment Risks: Delays or difficulties in enrolling sufficient patients for clinical trials could delay regulatory approvals and product launches [S1].
• Regulatory Compliance and Post-Market Risks: Ongoing regulatory oversight includes reporting requirements, advertising restrictions, and potential enforcement actions that could impact operations and reputation [S1].
Business trends: Continued clinical validation and regulatory submissions for TAEUS liver imaging devices, alongside strategic merger activities.
Execution milestones: Completion of FDA de novo clearance process, successful merger closing with Noble Africa, and expanded market access via CE mark and other approvals.
Key risks: Regulatory approval uncertainties, intellectual property challenges, merger completion risks, and clinical trial enrollment delays.
Very high visibility
Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).
- ENDRA Life Sciences Inc. develops medical devices, specifically ultrasound-based imaging technology called TAEUS for liver imaging applications.
- The TAEUS device has achieved MRI-level liver imaging precision and has shown strong consistency in clinical studies, indicating advanced clinical validation of the technology [N2][N3].
- ENDRA received CE mark approval for its TAEUS FLIP (Fatty Liver Imaging Probe) System in March 2020, allowing marketing in the European Union and other CE mark geographies [S1].
- The company is pursuing FDA regulatory clearance for its MASLD TAEUS device through a de novo classification process, which involves clinical studies to support a lower risk Class II designation; failure to obtain this clearance could require more rigorous PMA approval [S1].
- ENDRA's business is subject to extensive intellectual property risks, including patent maintenance costs, potential infringement litigation, and challenges in protecting trade secrets, which could impact competitive positioning [S1].
- The company faces regulatory risks including compliance with FDA, EMA, and other global medical device regulations, ongoing post-market surveillance, and advertising restrictions [S1].
- ENDRA reported a net loss of $1,528,528 and basic and diluted EPS of -1.02 USD per share for the quarter ended September 30, 2026 [S2].
- As of September 30, 2026, ENDRA had cash and equivalents of $1,516,523, current assets of $5,051,116, current liabilities of $635,724, a current ratio of 7.95, and a cash ratio of 2.39, indicating strong liquidity [S2].
- The company is advancing a merger with Noble Africa, subject to multiple conditions including stockholder approval and regulatory clearances, which may affect business focus and operations [S2].
- Trading of ENDRA shares was halted and resumed multiple times in late 2024 due to volatility and compliance issues, which have since been resolved [N7][N8].
Generated 2026-11-17
- S1 | 2026-03-31 | 10-K
- S2 | 2026-11-16 | 10-Q
- N1 | 2026-09-04 | www.nasdaq.com | ENDRA Shares Rise 12% As Q2 Loss Swings To Profit; Advances Noble Africa Merger | https://www.nasdaq.com/articles/endra-shares-rise-12-q2-loss-swings-profit-advances-noble-africa-merger
- N2 | 2026-03-03 | www.nasdaq.com | NDRA's TAEUS Device Achieves MRI-Level Liver Imaging Precision | https://www.nasdaq.com/articles/ndras-taeus-device-achieves-mri-level-liver-imaging-precision
- N3 | 2026-02-26 | www.nasdaq.com | ENDRA's TAEUS Liver Device Shows Strong Consistency In Clinical Study; Stock Up | https://www.nasdaq.com/articles/endras-taeus-liver-device-shows-strong-consistency-clinical-study-stock
- N4 | 2025-12-08 | www.nasdaq.com | Ascendiant Capital Maintains ENDRA Life Sciences (NDRA) Buy Recommendation | https://www.nasdaq.com/articles/ascendiant-capital-maintains-endra-life-sciences-ndra-buy-recommendation
- N5 | 2025-10-16 | www.nasdaq.com | Merit Medical Expands GI Portfolio With $22M C2 CryoBalloon Acquisition | https://www.nasdaq.com/articles/merit-medical-expands-gi-portfolio-22m-c2-cryoballoon-acquisition
- N6 | 2025-10-13 | www.nasdaq.com | Pulse Biosciences Unveils Promising First-in-Human Data for nPulse | https://www.nasdaq.com/articles/pulse-biosciences-unveils-promising-first-human-data-npulse
- N7 | 2024-11-29 | www.nasdaq.com | ENDRA Life Sciences Inc trading resumes | https://www.nasdaq.com/articles/endra-life-sciences-inc-trading-resumes
- N8 | 2024-11-29 | www.nasdaq.com | ENDRA Life Sciences Inc trading halted, volatility trading pause | https://www.nasdaq.com/articles/endra-life-sciences-inc-trading-halted-volatility-trading-pause
This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Generated by Valye SEC Pipeline Engine
.gif)


